Literature DB >> 29707301

Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery.

Sjoerd M Lagarde1, Martinus C J Anderegg1, Suzanne S Gisbertz1, Sybren L Meijer2, Maarten C C M Hulshof3, Jacques J G H M Bergman4, Hanneke W M van Laarhoven5, Mark I van Berge Henegouwen1.   

Abstract

BACKGROUND: The aim of the present study is to identify the incidence and prognostic significance of lymph node metastases near the celiac trunk in patients who underwent neoadjuvant chemo(radio)therapy followed by esophagectomy.
METHODS: Between March 1994 and September 2013 a total of 462 consecutive patients with cancer of the esophagus or gastroesophageal junction (GEJ) who underwent potentially curative esophageal resection after neoadjuvant chemotherapy (N=88; 19.0%) or neoadjuvant chemoradiotherapy (CRT) (N=374; 81.0%) were included.
RESULTS: Seventy one (15.4%) patients had truncal node metastases in the resection specimen. Metastases to these nodes occurred more frequently in male patients with adenocarcinoma and in tumors at the gastro-esophageal junction. A lower response to neoadjuvant treatment, higher ypT and ypN stages and a poorer grade of differentiation were significantly related with truncal node metastases. Patients with tumor positive truncal nodes had a worse median overall survival (17 vs. 55 months). In multivariate analysis, truncal node metastases were independently associated with a worse survival. Only 22 (31.0%) of the 71 patients with tumor positive truncal nodes were identified preoperatively with EUS or CT. In contrast, 37 patients had suspicious truncal nodes on EUS or CT, but metastases in the pathology specimen were absent.
CONCLUSIONS: In the present study, it is demonstrated that positive truncal nodes in the resection specimen after neoadjuvant therapy, are associated with advanced tumor stages and are an independent factor for inferior survival.

Entities:  

Keywords:  Esophageal carcinoma; neoadjuvant therapy; truncal node metastases

Year:  2018        PMID: 29707301      PMCID: PMC5906332          DOI: 10.21037/jtd.2018.02.81

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  27 in total

1.  Predicting individual survival after potentially curative esophagectomy for adenocarcinoma of the esophagus or gastroesophageal junction.

Authors:  Sjoerd M Lagarde; J B Reitsma; F J W Ten Kate; O R C Busch; H Obertop; A H Zwinderman; J Moons; J J B van Lanschot; T Lerut
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

2.  Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography.

Authors:  M A Eloubeidi; M B Wallace; B J Hoffman; M B Leveen; A Van Velse; R H Hawes; C E Reed
Journal:  Ann Thorac Surg       Date:  2001-07       Impact factor: 4.330

3.  Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction.

Authors:  C van de Ven; P De Leyn; W Coosemans; D Van Raemdonck; T Lerut
Journal:  Eur J Cardiothorac Surg       Date:  1999-06       Impact factor: 4.191

4.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

5.  Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Authors:  Carlo Castoro; Marco Scarpa; Matteo Cagol; Alberto Ruol; Francesco Cavallin; Rita Alfieri; Gianpietro Zanchettin; Massimo Rugge; Ermanno Ancona
Journal:  Ann Surg Oncol       Date:  2011-05-10       Impact factor: 5.344

6.  Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction.

Authors:  Brechtje A Grotenhuis; Bas P L Wijnhoven; Jan Werner Poley; John J Hermans; Katharina Biermann; Manon C W Spaander; Marco J Bruno; Hugo W Tilanus; J Jan B van Lanschot
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

7.  The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic.

Authors:  David A Schomas; J Fernando Quevedo; James M Donahue; Francis C Nichols; Yvonne Romero; Robert C Miller
Journal:  Dis Esophagus       Date:  2009-06-09       Impact factor: 3.429

8.  A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery.

Authors:  M Albregts; M C C M Hulshof; P J Zum Vörde Sive Vörding; J J B van Lanschot; D J Richel; H Crezee; P Fockens; J D P van Dijk; D González González
Journal:  Int J Hyperthermia       Date:  2004-09       Impact factor: 3.914

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement.

Authors:  J J Boonstra; L B Koppert; B P Wijnhoven; H W Tilanus; H Van Dekken; T C K Tran; A Van der Gaast
Journal:  J Surg Oncol       Date:  2009-10-01       Impact factor: 3.454

View more
  2 in total

1.  Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis.

Authors:  Stefano de Pascale; Paolo Parise; Michele Valmasoni; Jacopo Weindelmayer; Fabrizia Terraneo; Chiara Alessandra Cella; Simone Giacopuzzi; Andrea Cossu; Simonetta Massaron; Ugo Elmore; Stefano Merigliano; Uberto Fumagalli Romario
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

2.  Prognostic significance of middle paraesophageal lymph node metastasis in resectable esophageal squamous cell carcinoma: A STROBE-compliant retrospective study.

Authors:  Huang Hong; Hou Jie; Rao Liyu; Chen Zerui; Shu Borong; Liang Hongwei
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.